Sorafenib Chemoembolization Evaluation Controlled Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).

PROCEDURE

TACE

"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."

Trial Locations (1)

710032

Xijing Hospital of Digestive Disease, Xi'an

All Listed Sponsors
lead

Air Force Military Medical University, China

OTHER

NCT01906216 - Sorafenib Chemoembolization Evaluation Controlled Trial | Biotech Hunter | Biotech Hunter